H.C. Wainwright Upholds Buy and $10 Target for Invivyd Ahead of Anticipated Phase 3 Data
H.C. Wainwright reaffirmed its Buy stance on Invivyd Inc., maintaining a $10 price target, following a recent dialogue with the company’s leadership. This valuation implies substantial upside relative to the current stock price, reflecting confidence in Invivyd’s forthcoming Phase 3 results for VYD2311 and growth from the PEMGARDA franchise. The co…